1 published article · Updated continuously
12 trials tracked for Knee Arthritis: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 14 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical evidence indicates that specific pharmacological and procedural interventions impact postoperative outcomes for knee arthritis. The use of Amicar was associated with significantly lower total blood loss, fewer transfusions, and less decrease in pre-operative to lowest post-operative hemoglobin levels (p<0.05) 2. Additionally, the administration of Exparel resulted in a shorter hospital length of stay (p<0.05), reduced inpatient opioid use (p<0.05), and significant improvements in Numeric Rating Scale (NRS) pain scores (p<0.05) 5.
In terms of patient response to specific treatments, a 4 mL injection of Ampion resulted in a significantly higher number of participants classified as responders compared to the control group (p<0.0001) 4. Morphine was evaluated for its impact on the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr), showing an increase from pre-operative scores (52.0; 51.4) to two weeks postoperatively (64.0; 71.5) 1.
Other established interventions included Customized Patient Instrumentation 3 and the trumatch group 6.
AI synthesis of 7 cited trials, updated Aug 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
